Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications
![Thumbnail](/bitstream/handle/10576/46831/s41467-022-28639-4.pdf.jpg?sequence=3&isAllowed=y)
عرض / فتح
التاريخ
2022المؤلف
Al-Nesf, Maryam A. Y.Abdesselem, Houari B.
Bensmail, Ilham
Ibrahim, Shahd
Saeed, Walaa A. H.
Mohammed, Sara S. I.
Razok, Almurtada
Alhussain, Hashim
Aly, Reham M. A.
Al Maslamani, Muna
Ouararhni, Khalid
Khatib, Mohamad Y.
Hssain, Ali Ait
Omrani, Ali S.
Al-Kaabi, Saad
Al Khal, Abdullatif
Al-Thani, Asmaa A.
Samsam, Waseem
Farooq, Abdulaziz
Al-Suwaidi, Jassim
Al-Maadheed, Mohammed
Al-Siddiqi, Heba H.
Butler, Alexandra E.
Decock, Julie V.
Mohamed-Ali, Vidya
Al-Ejeh, Fares
...show more authors ...show less authors
البيانات الوصفية
عرض كامل للتسجيلةالملخص
COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients. 2022, The Author(s).
المجموعات
- الأبحاث [709 items ]
- أبحاث فيروس كورونا المستجد (كوفيد-19) [799 items ]